Relationships between osteoprotegerin, receptor activator of the nuclear factor kB ligand serum levels and carotid intima-media thickness in patients with type 2 diabetes mellitus

Panminerva Medica

Volumn 56, Issue 3, 2014, Pages 221-225

  Gaudio, A ^a   Privitera, F ^a   Pulvirenti, I ^a   Canzonieri, E ^a   Rapisarda, R ^a   Fiore, C E ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Carotid intima media thickness; Diabetes mellitus; Osteoprotegerin; Type 2

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTERIAL WALL THICKNESS; BODY MASS; CAROTID ARTERY; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; POSTMENOPAUSE; REPRODUCIBILITY; SEX DIFFERENCE; VASCULAR DISEASE;

ADULT; AGE FACTORS; AGED; BODY MASS INDEX; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPROTEGERIN; POSTMENOPAUSE; RANK LIGAND; REPRODUCIBILITY OF RESULTS; SEX FACTORS; ULTRASONOGRAPHY; VASCULAR DISEASES;

EID: 84927172300     PISSN: 00310808     EISSN: 18271898     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chen NX, Moe SM. Arterial calcification in diabetes. Curr Diab Rep 2003;3:28-32.
2. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes 1996;45(Suppl3):S14-6.
3. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
4. Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes-part I: pathways of vascular disease in diabetes. Vascul Pharmacol 2011;54:68-74.
5. Schwartz Ann V. Clinical aspects of diabetic bone disease: an update. Clinical Rev Bone Miner Metab 2013;11:17-27.
6. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29:155-92.
7. Heymann MF, Herisson F, Davaine JM, Charrier C, Battaglia S, Passuti N et al. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. Cytokine 2012;58:300-6.
8. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-7.
9. Augoulea A, Vrachnis N, Lambrinoudaki I, Dafopoulos K, Iliodromiti Z, Daniilidis A et al. Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int J Endocrinol 2013;2013:182060.
10. Ishiyama M, Suzuki E, Katsuda J, Murase H, Tajima Y, Horikawa Y et al. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res Clin Pract 2009;85:189-96.
11. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circulation Res 2004;95:1046-57.
12. Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I et al. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:3744-50.
13. Bauer M, Caviezel S, Teynor A, Erbel R, Mahabadi AA, Schmidt-Trucksäss A. Carotid intima-media thickness as a biomarker of subclinical atherosclerosis. Swiss Med Wkly 2012;142:w13705.
14. van den Oord SC, Sijbrands EJ, Ten Kate GL, van Klaveren D, van Domburg RT van der Steen AF et al. Carotid intima-media thickness for cardiovascular risk assessment: Systematic review and meta-analysis. Atherosclerosis 2013;228:1-11.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28:S37-S42.
16. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol 2010;55:1600-7.
17. Grigoropoulou P, Eleftheriadou I, Zoupas C, Tentolouris N. The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. Curr Med Chem 2011;18:4813-9.
18. Giaginis C, Papadopouli A, Zira A, Katsargyris A, Klonaris C, Theocharis S. Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor KB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis. Med Sci Monit 2012;8:CR597-604.
19. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006;4:801-11.
20. Scoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.
21. Browner WS, Lui LY, Cummings SR. Association of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-7.
22. Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 2007;116:385-91.
23. Schoppet M, Schaefer JR, Hofbauer LC. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 2003;107:e76.
24. Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (London) 2005;209:389-95.
25. Mori K, Jono S, Emoto M, Kawagishi T, Yasumoto H, Konishi T et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology 2010;61:86-91.
26. Findlay DM, Atkins GJ. Relationship between serum RANKL and RANKL in bone. Osteoporos Int 2011;22:2597-602
27. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-72.
28. Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab 2009;27:464-70.